Arca
Skip to content

UCB4940 (CDP4940): Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761151's history or UGB, Inc.'s company page.

On May 12, 2022, FDA declined to approve UCB4940 (CDP4940) (BLA 761151) from UGB, Inc. in its present form, citing facility inspections. The application was later approved.

  • Letter date: May 12, 2022
  • Application: BLA 761151
  • Since then: Approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Facility inspections

The Letter

Text from openFDA

During a recent inspection of the UCB Pharma SA (FEI: 3003909356) manufacturing facility for this application, our field investigator conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before...… openFDA did not return the full text just now. Open it in the letter search.

Record

Company
UGB, Inc.
Application
BLA 761151
Status in openFDA
Approved
Review division
Office of Immunology and Inflammation

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.